J&J scraps a multi­bil­lion-dol­lar he­pati­tis C pro­gram af­ter ri­vals divvy up the mar­ket

Af­ter com­mit­ting bil­lions of dol­lars to a new he­pati­tis C cock­tail that had the po­ten­tial to com­pete with the al­ready deeply en­trenched ri­vals on the mar­ket, J&J is call­ing it quits.

Drawn to he­pati­tis C at a time when the field was un­der­go­ing a dra­mat­ic shift in com­ing up with a pain­less res­o­lu­tion of the dis­ease, that work is now done. Gilead led the way in cur­ing hep C, fol­lowed by a slew of com­peti­tors who have been whit­tling down the cost as they scram­bled to find new and bet­ter ways to do the job ever quick­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.